<DOC>
	<DOCNO>NCT00002030</DOCNO>
	<brief_summary>To evaluate safety , tolerability , efficacy long term , bi-weekly administration aerosol pentamidine use prophylactic agent patient least two episode AIDS-associated Pneumocystis carinii pneumonia ( PCP ) .</brief_summary>
	<brief_title>An Open Label Study Evaluate Long-Term Safety Effectiveness Aerosol Pentamidine Prophylaxis Pneumocystis Carinii Pneumonia AIDS Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) . Standard experimental treatment opportunistic infection neoplasm ( include aerosolize intravenous pentamidine ) develop study . Concurrent Treatment : Allowed : Any standard experimental treatment opportunistic infection neoplasm develop study . Patients must AIDS least one cytologically histologically proven episode Pneumocystis carinii pneumonia ( PCP ) . Patients must free acute medical problem . Prior Medication : Allowed : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Requiring ongoing active therapy opportunistic infection time study entry . Toxoplasmosis . Cryptococcus . Pulmonary Kaposi 's sarcoma ( KS ) . Asthma poorly control medication . Concurrent Medication : Excluded : Pentamidine route aerosolize intravenous experimental agent chemoprophylaxis PCP study ( e.g . : Septra , Fansidar , Dapsone , eflornithine ) . Concurrent Treatment : Excluded : Transfusion dependency define &gt; 1 blood transfusion per month . Patients follow exclude : Requiring ongoing active therapy opportunistic infection ( O.I . ) time entry either Toxoplasmosis cryptococcosis entry . Pulmonary Kaposi 's sarcoma ( KS ) . Active substance abuse patient comply study procedure . Unwilling sign inform consent . In opinion investigator cooperate study procedure . Asthma poorly control medication . Patients may receive pentamidine route aerosolize intravenous experimental agent chemoprophylaxis PCP study ( e.g . : Septra , Fansidar , Dapsone , eflornithine ) . Prior Medication : Excluded within 30 day study entry : Antiretroviral agent , exclude zidovudine ( AZT ) . Immunomodulating agent . Corticosteroids . Prior Treatment : Excluded within 7 day study entry : Blood transfusion . Excluded : Requiring ongoing active treatment opportunistic infection time study entry . Active substance abuse patient comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1989</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Aerosols</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>